Nebraska Center for Integrated Biomolecular Communication (CIBC)

项目摘要/摘要 生物分子通讯通路的调节是维持生理功能的关键。拆解 这些途径和填补关键知识空白将提供新的机会来了解、诊断、 治疗人类疾病。在第一阶段，内布拉斯加州集成生物分子通信中心 (CIBC)支持15名早期调查人员(ESIS)，帮助该大学招聘4名新教职员工 内布拉斯加州-林肯大学(UNL)，并建立了两个研究中心。加拿大帝国商业银行的Esis获得了1670万美元的外部资金 研究基金，并撰写了82份同行评议的出版物。在第一阶段的基础上，CIBC在第一阶段的目标 2是继续建设一支关键的生物医学研究人员队伍，并在 UNL的生物分子通信通路区域，将使CIBC成功过渡到长时间 第三阶段的任期可持续性。CIBC将继续发展多学科团队来审问复杂 疾病途径，特别是通过连接研究人员开发新的分子探针和分析 这些技术揭开了人类疾病的分子机制。加拿大帝国商业银行第二阶段的具体目标 是：1)通过支持研究工作和事业，加强UNL的生物医学研究基础设施 生物医学研究人员的发展，其研究广泛集中于了解 与生物医学相关的交流途径；2)通过维护和扩展提高研究能力 系统生物学核心(SBC)，以促进必要的生物分析数据和数据与生命的获取 Sciences Core(DLSC)提供关键的生物信息学支持以及数据管理、存储和共享 中心成员；以及3)促进具有广泛学科代表性的跨学科研究合作 从不同的角度对复杂疾病进行高影响力的研究。最初的第二阶段项目 领袖们将通过他们对生物分子不同方面的基本关注来追求相互关联的项目 疾病相关沟通途径的基础。这些项目，标志着CIBC的跨学科 1)开发新的化学探针和靶向质谱学方法 研究可卡因和苯丙胺调节的转录肽和受体(S)，2)了解 7SK RNP调控转录及其在人类疾病中的意义，3)进行近实时检测 一种通用型电化学肽生物传感技术检测耐甲氧西林金黄色葡萄球菌 4)开发了一种新的基于非天然氨基酸的染色质分离方法(UChIMe)。 提高了准确性和灵敏度。CIBC将进一步扩大SBC和DLSC，使内布拉斯加州的生物医学 研究人员进行高影响力的生物医学研究。CIBC的创新之处在于整合了研究活动 化学家、生物化学家、工程师和生物信息学家，以了解细胞如何交流和整合 与疾病发展和进展相关的代谢和调节途径。

PROJECT SUMMARY/ABSTRACT Regulation of biomolecular communication pathways is critical to maintaining physiological function. Unraveling these pathways and filling in critical knowledge gaps will provide novel opportunities to understand, diagnose, and treat human diseases. During Phase 1, the Nebraska Center for Integrated Biomolecular Communication (CIBC) supported 15 early stage investigators (ESIs), helped recruit four new faculty members to the University of Nebraska-Lincoln (UNL), and established two research cores. CIBC’s ESIs secured $16.7 million in external research funds and authored 82 peer-reviewed publications. Building on Phase 1, the goal of the CIBC in Phase 2 is to continue building a critical mass of biomedical investigators and supporting research infrastructure in the area of biomolecular communication pathways at UNL that will position CIBC for a successful transition to long- term sustainability in Phase 3. CIBC will continue to develop multidisciplinary teams to interrogate complex disease pathways, especially by connecting researchers developing new molecular probes and analytical techniques with those unravelling molecular mechanisms of human diseases. CIBC’s Phase 2 specific aims are to: 1) strengthen UNL’s biomedical research infrastructure by supporting the research efforts and career development of biomedical investigators whose research is broadly focused on understanding the regulation of biomedically relevant communication pathways; 2) enhance research capabilities by maintaining and expanding the Systems Biology Core (SBC) to facilitate acquisition of essential bioanalytical data and the Data and Life Sciences Core (DLSC) to provide critical bioinformatics support and data management, storage, and sharing to Center members; and 3) advance interdisciplinary research collaborations with broad disciplinary representation to pursue high-impact research into complex disease from diverse perspectives. The initial Phase 2 Project Leaders will pursue projects interrelated by their fundamental focus on different aspects of the biomolecular basis of disease-associated communication pathways. These projects, which signify CIBC’s interdisciplinary nature, are directed toward: 1) developing novel chemical probes and targeted mass spectrometry approaches to study the cocaine and amphetamine-regulated transcript peptide and receptor(s), 2) understanding how the 7SK RNP regulates transcription and its implications in human diseases, 3) conducting near real-time detection of methicillin-resistant S. aureus by developing a generalizable electrochemical peptide-based biosensing platform, and 4) developing a novel Unnatural Amino Acid-based Chromatin Isolation Method (UChIMe) with improved accuracy and sensitivity. CIBC will further expand SBC and DLSC to enable Nebraska’s biomedical researchers to pursue high-impact biomedical research. CIBC’s innovation is in integrating the research activities of chemists, biochemists, engineers, and bioinformaticians to understand how cells communicate and integrate metabolic and regulatory pathways relevant to disease development and progression.